Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives

Table 2

Studies carried out with lipid-based nanosystems as RNAi delivery vectors against hepatitis C (HCV).

Lipid nanosystem	RNAi	Targeting molecule	Culture cells	In vivo model	Reference
Cationic liposomes	siRNAs against the 5′-UTR and 3′-UTR of the HCV genome	Lactosylated-PE	FLR3-1 and; R6FLR-N cells	CN2-29 transgenic mice	[33]
Cationic liposomes	HCV-core specific siRNA (siHCc)	Apo A-I	Huh7	HCV mouse model constructed by hydrodynamic injection of DNA plasmid expressing viral proteins	[34]
Cationic liposomes	HCV-core specific siRNA (siHCc)	Recombinant human apo A-I	—	HCV mouse model constructed by hydrodynamic injection of DNA plasmid expressing viral proteins	[35]
Cationic nanosomes	siRNAs against hte stem-loop domains II–IV of HCV 5′UTR	—	Huh-7.5 and R4-GFP cells	HCC tumor-xenograft mice model for HCV	[36]
Cationic LNP	sshRNA targeting the HCV IRES	—	—	Reporter mice that express in the liver firefly luciferase under the control of the HCV IRES	[37]

Lactosylated-PE: lactosylated-phosphatidylethanolamine; FLR3-1 cells: HuH-7 cells bearing an HCV subgenomic replicon (genotype 1b); R6FLR-N cells: HuH-7 cells bearing an HCV subgenomic replicon (genotype 1b); CN2-29 transgenic mice: mice that carry an HCV transgene; Apo A-I: apolipoprotein A-I; Huh7 cells: human hepatoma cell line; Huh7.5 cells: Huh7 cells that contain a mutation in RIG-I believed to be responsible for the improved replication of HCV; R4-GFP cells: IFN--resistant HCV-GFP chimer replicon cell line; HCC: hepatocellular carcinoma; LNP: lipid nanoparticles; IRES: internal ribosome entry site.